Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety".

Yamamoto, Hiroyasu; Nobori, Kiyoshi; Matsuda, Yoshimi; Hayashi, Yasuhiro; Hayasaki, Takanori; Akizawa, Tadao

Yamamoto, Hiroyasu; Nobori, Kiyoshi; Matsuda, Yoshimi; Hayashi, Yasuhiro; Hayasaki, Takanori; Akizawa, Tadao.

Afiliação

Yamamoto H; Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Nobori K; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Matsuda Y; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Hayashi Y; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
Hayasaki T; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
Akizawa T; Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Am J Nephrol ; 52(12): 977-978, 2021.

Article em En | MEDLINE | ID: mdl-34727543

Assuntos

Anemia; Inibidores de Prolil-Hidrolase; Humanos; Prolina Dioxigenases do Fator Induzível por Hipóxia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Prolil-Hidrolase / Anemia Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google